Figure 4
Five-year probabilities of OS after T cell–replete, ATG-containing, and alemtuzumab-containing transplantations adjusted for age at transplantation, disease status at transplantation, graft type, and transplantation period.
Five-year probabilities of OS after T cell–replete, ATG-containing, and alemtuzumab-containing transplantations adjusted for age at transplantation, disease status at transplantation, graft type, and transplantation period.
